Inovio Pharmaceuticals, Inc. (NYSE: INO) and its subsidiaries engage in discovering and developing synthetic vaccines and immune therapies for cancers and other infectious diseases. Inovio’s DNA-based SynCon technology facilitates the design of vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza, while its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. For more information, visit the company’s website at www.inovio.com.